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BACKGROUND: Elevated blood glucose level is a major factor in development of diabetic complications due to unfavorable hyperglycemic 
induced biochemical as well as hematological indices 
changes.  The  aim of  this  study  was  to  evaluate  the 
correlation   between   glycemic   characteristic   and 
erythrocyte  indices  in  obese  subjects  with  different 
glycemic status. 
METHODS: Cross cross-sectional study was designed, 
and 80 obese subjects were enrolled. The correlations 
between glycemic characteristic (fasting plasma glucose 
(FPG), postprandial plasma glucose (PPG), hemoglobin 
A1c (HbA1c) and homeostasis model assessment of insulin 
resistance (HOMA-IR)) and erythrocyte indices (Hb, red 
blood count (RBC), mean corpuscular volume (MCV), 
mean corpuscular hemoglobin (MCH) and mean corpuscular 
hemoglobin concentration  (MCHC)) were evaluated. 
RESULTS: Of 80 obese subjects with different glycemic 
status, there were 48 patients with only obesity (HbA1c 
<5.7%), 19 patients with pre-diabetes (HbA1c 5.7-6.4%) 
and 13 patients with diabetes (HbA1c >6.4%). Glycemic 
characteristic and profile lipid (high-density lipoprotein 
cholesterol (HDL-C), triglycerides (TG)) were differ 
significantly in the different HbA1c level. Erythrocyte 
indices  were   not  differ  significantly  in  the  different 
HbA1c level. Partial Spearman's correlation analysis 
showed  that  only  MCV  was  significantly  correlated 
with glycemic  characteristic of FPG, PPG,  HbA1c  and 
HOMA-IR  (r=-0.36, p=0.001; r=-0.29, p=0.007; r=-0.27, 
p=0.014 and r=-0.236, p=0.035; respectively).
CONCLUSION: MCV was significantly correlated with 
glycemic characteristic (FPG, PPG, HbA1C and HOMA-
IR). Further investigations are recommended.
KEYWORDS: MCV, glycemic-characteristic, HbA1c, 
erythrocyte indices
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Abstract
Introduction
Hemorheological inflammatory parameters in diabetes 
mellitus are often disturbed. Red cells of patients with 
type 2 diabetes are known to aggregate more readily than 
those of normal subjects, with excessive aggregation 
of red  cells  considered  one  of  the  most  prominent 
features  in diabetes  patients  with  poor  glycemic  control. 
Erythrocyte  aggregation  directly  affects  the  viscosity 
of  whole  blood.(1) The major determinants of erythrocyte 
deformability include cell shape (i.e., the surface-to-volume 
ratio); the mechanical properties of the cell membrane 
and its cytoskeleton; and intracellular viscosity, which are 
related to mean cell hemoglobin concentration.(2)
 Study has been reported that blood viscosity is 
significantly increased in 64 patients suffering from long-
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standing diabetes compared to non-diabetic control.(3) 
This increase was most pronounced in the proliferative 
retinopathy or nephropathy, and low in myocardial 
ischemia, or peripheral artery disease (PAD). Erythrocyte 
deformability was lower in the 14 diabetic patients with 
the most extensive microangiopathy than in the 22 diabetes 
patients with slight or no complications and in controls. 
These findings suggest that hyper viscosity and reduce 
the deformability of erythrocytes may be an important 
factor and can potentially be treated in the etiology or 
microcirculatory disease in diabetes. Hemorheological 
disorders may promote stagnation of blood flow in the 
capillaries and post-capillary venules of diabetes patients. 
Circulatory stagnation is thought to play an etiological 
role in capillary non-perfusion, acting as a stimulus for 
new vessel formation. The latter is regarded as a major 
cause of blindness in diabetes patients.(4) Independently, 
high  values of  HbA1c  are  associated  deformability  of 
erythrocytes.(5)
 Glycosylated hemoglobin A1c (HbA1c) is an important 
biomarker, which represents the average of fasting or 
prandial blood glucose during the previous 2-3 months.(6) 
HbA1c is regarded as an important tool in diabetes diagnosis 
and management.(7) Elevated HbA1c levels are indicative 
of long-term insulin resistance, which may accompany 
hyperglycemia, dyslipidemia, hypercoagulability, and 
systemic inflammatory responses.(8)  
 The study shows a significant increase in all 
erythrocyte indices in diabetic patients as compared to 
control group. Significant increase was also observed in red 
blood cell (RBC), hemoglobin, hematocrit (HCT), mean 
corpuscular hemoglobin concentration (MCHC) and red 
cell distribution width (RDW) in both males and females 
patients when compared to controls.(9,10)
 The aim of the present study was to evaluate the 
correlation  between  glycemic  characteristic  and 
erythrocyte indices in obese with the different glycemic 
status.
Methods
Study Population
Cross cross-sectional study was designed, and 80 obese 
subjects were enrolled. Obese  was  defined  as body mass 
index (BMI) ≥25 kg/m2.(10) Furthermore, the patients 
were subdivided according to the glycemic  control  state 
into  a  good  glycemic  control group  (HbA1c <5.7),  fair 
glycemic  control  group  (HbA1c ≥5.7-6.4)  and  poor 
glycemic control group  (HbA1c ≥6.5).(11)  Subjects with 
secondary  obese  due  to,  for  example, endocrine  disease 
was  excluded, as  were  subjects  taking  steroids,  and those 
with infectious, hepatic, renal, or hematologic diseases. The 
study protocol was  approved  by  The  Health  Research 
Ethical  Committee Faculty of Medicine, University of 
Sumatera Utara/H. Adam Malik  General  Hospital (No.53/
KOMET/FK USU/2015).
Laboratory Assays
Venous blood samples were collected from subjects 
in the morning after a 10-12 hour fast, into plain, 
ethylenediaminetetraacetate (EDTA)-containing and 
heparin-containing vacutainers. Plain and EDTA-containing 
vacutainers were centrifuged. HbA1c was measured in 
EDTA-containing serum. Fasting plasma glucose (FPG), 
plasma high-density lipoprotein-cholesterol (HDL-C) 
and low-density lipoprotein-cholesterol (LDL-C) were 
measured by Architect Ci 8200 (Abbot, Illinois, USA) 
and triglycerides (TG) by GPO-PAP method. High 
sensitivity C-reactive protein (hs-CRP) was measured by 
an immunoturbidimetric assay (Siemens Diagnostics, Los 
Angeles, USA), insulin (Siemens Diagnostic, Los Angeles, 
USA) and adiponectin were measured by Elisa (Daiichi, 
Tokyo, Japan). Homeostasis model assessment of insulin 
resistance (HOMA-IR) were calculated from fasting glucose 
and insulin concentrations by formula of Matthews.(12)
Statistical Analysis
All  statistical analysis using SPSS Statistics V22.0. Data 
were  expressed  as mean±standard  deviation  and comparison 
of  data  using one-way ANOVA. The correlation  between 
glycemic characteristic and erythrocyte indices were 
determined by Spearman’s correlation  analysis. p-value 
<0.05  was  considered  as  statistically  significant. 
A total of 80 subjects was enrolled in this study. There were 
48 subjects with  HbA1c <5.7%, 19  subjects  with  HbA1c 
5.7-6.4% and 13 subjects with HbA1c >6.4%. The average 
glycemic characteristic (FPG, postprandial plasma glucose 
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(PPG), fasting insulin, HOMA-IR and HbA1C) were 
95.70±36.00 mg/dL; 94.83±21.55 mg/dL; 8.991±7.93μIU/
mL; 2.37±3.02 and 5.94±1.30; respectively, the average 
erythrocyte indices (Hb, RBC, mean corpuscular volume 
(MCV), mean corpuscular hemoglobin (MCH) and MCHC) 
were 13.62±1.35; 4.77±0.41; 86.15±6.81; 28.66±2.65; and 
33.23±1.29; respectively. 
 General characteristics and laboratory data of groups 
(lipid profile, hs-CRP and adiponectine) enrolled in the study 
are  shown  in  Table 1. One-way ANOVA test showed that 
glycemic indices (FPG, PPG, fasting insulin and HOMA-
IR)  were  differ  significantly  in  the  different HbA1c 
level.  Otherwise, erythrocyte  indices  (Hb,  RBC, MCV, 
MCH  and  MCHC)  were  not  differ  significantly  but 
having  trend  toward  to  decline.  Lipid  profile  (LDL-C, 
HDL-C and TG) and inflammatory characteristic (hs-CRP 
and  adiponectin) were not differ significantly (Table 2). 
Meanwhile, the result of Partial Spearman's correlation 
analysis showed that only  MCV was significantly correlated 
with all glycemic characteristic:  FPG,   PPG,  HbA1c  and 
HOMA-IR  (r=-0.36,  p=0.001;  r=-0.29, p=0.007; r=-0.27, 
p=0.014 and r=-0.236, p=0.035; respectively), but MCH and 
MCHC were not significantly correlated with all glycemic 
characteristic (Table 3).
Table 1. Clinical and biochemical characteristics of obese subjects. 
WC: waist circumference; CRP: C-reactive protein; MPV: mean platelet volume; WBC: white blood cell. 
Characteristic Total (mean±SD)
n 80
Age (year) 38.95±8.14
BMI (kg/m2) 31.74±5.21
WC (cm) 91.95±9.59
FPG (mg/dL) 95.70±36.00
PPG (mg/dL) 94.83±21.55
Fasting insulin (μIU/mL) 8.991±7.93
HOMA-IR 2.37±3.02
HbA1c (%) 5.94±1.30
LDL-C (mg/dL) 138.12±32.40
HDL-C (mg/dL) 53.72±16.73
TG (mg/dL) 131.30±75.92
hs-CRP (mg/dL) 4.24±3.86
Adiponectin (μg/dL) 4.42±2.40
WBC (103/μL) 7.76±1.62
Thrombocytes (103/μL) 307.22±70.09
Hb (g/dL) 13.62±1.35
RBC (M/mm3) 4.77±0.41
MCV (fL) 86.15±6.81
MCH (pg) 28.66±2.65
MCHC (g/dL) 33.23±1.29
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Table 2. Comparison of hematological indices and various parameters in the different HbA1c level. 
p-value between HbA1c (One-way ANOVA test), *p<0.05. 
Table 3. Correlation between glycemic characteristic and hematological.
*p<0.05. 
HbA1c levels
HbA1c <5.7 
(mean±SD)
HbA1c 5.7-6.4 
(mean±SD)
HbA1c >6.4 
(mean±SD)
n 48 19 13
BMI (kg/m2) 31.17±4.91 31.97±3.88 33.50±7.57 0.356
WC (cm) 90.45±8.49 92.10±7.48 97.27±14.13 0.074
FPG (mg/dL) 81.94±9.57 97.63±34.12 143.69±56.28 0.000*
PPG (mg/dL) 94.83±21.55 48.50±11.13 97.97±27.17 0.000*
Fasting insulin (μIU/mL) 7.06±6.12 12.24±11.39 11.38±5.89 0.025*
HOMA-IR 1.53±1.23 3.51±5.35 3.81±1.96 0.008*
LDL-C (mg/dL) 136.39±32.93 136.89±32.39 146.30±31.67 0.614
HDL-C (mg/dL) 57.56±18.55 49.00±12.18 46.46±11.01 0.037*
TG (mg/dL) 112.70±47.931 154.73±61.20 165.69±140.71 0.023*
hs-CRP (mg/dL) 4.34±4.26 3.40±2.30 5.06±4.07 0.471
Adiponectin (μg/dL) 4.67±2.39 3.83±1.82 4.32±3.12 0.433
WBC (103/µL) 7.80±1.63 7.46±1.65 8.07±1.58 0.574
Thrombocytes (103/µL) 306.25±75.83 295.84±55.99 327.46±66.82 0.456
Hb (g/dL) 13.73±1.33 13.58±0.95 13.30±1.90 0.606
RBC (M/mm3) 4.71±0.33 4.83±0.46 4.88±0.55 0.291
MCV (fL) 87.43±6.09 85.14±5.96 82.92±9.34 0.079
MCH (pg) 29.18±2.36 28.25±2.29 27.33±3.63 0.061
MCHC (g/dL) 33.34±1.26 33.16±1.04 32.89±1.72 0.525
p  valueCharacteristic
r p r p r p r p
WBC (103/µL) 0.5 0.1 0.3 0.1 0.1 0.6 0.3 0.008*
Thrombocytes  (103/µL) 0.18 0.098 0.61 0.056 0.07 0.507 0.33 0.003*
Hb (g/dL) -0.52 0.072 -0.25 0.129 -0.1 0.377 0.08 0.483
RBC (M/mm3) 0.3 0.116 0.67 0.047* 0.04 0.69 0.21 0.064
MCV (fL) -0.36 0.001* -0.29 0.007* -0.27 0.014* -0.24 0.035*
MCH (pg) -0.3 0.006* -0.2 0.1 -0.2 0.047* -0.2 0.1
MCHC (g/dL) 0.1 0.3 0.4 0.1 -0.3 0.004* 0.0 0.7
Characteristic
FPG value PPG value HbA1c value HOMA-IR value
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Variable or persistent hyperglycemia induces changes in 
the erythrocyte membrane and its cytoplasm, leading to 
modifications in erythrocyte deformability.(13,14) Elevated 
glucose concentration is a major factor affecting erythrocyte 
morphology.(15) As diabetic conditions are prolonged, the 
deformability of erythrocytes is further reduced, while their 
aggregation increases, making whole blood more viscous 
and  possibly obscuring the flow of red cells in micro 
vessels.(16) 
 Several pathophysiological disorders, including 
rheological disorders of RBCs and decreased RBC 
deformability, were found to be involved in the development 
of diabetic microangiopathy.(13,14) Impaired erythrocyte 
deformability has been attributed to alterations in membrane 
structure, including alterations in the ratio of cholesterol to 
phospholipids in the lipid membrane core and amplified 
peroxidation. 
 In the previous study, prior exposure of the 
erythrocytes to carbon monoxide (known to inhibit heme-
protein degradation) prevented almost completely the 
loss in  deformability  caused  by hydrogen  peroxide  to 
the extent of malonyldialdehyde (an indicator of lipid 
peroxidation)  and  alanine production  (an indicator of 
protein degradation).(16) The study was carried out to 
evaluate the influence of dyslipidemia  in patients with 
stable angina on some rheological properties of the 
erythrocytes. This study revealed that atherogenic lipids 
increased erythrocyte’s aggregation, but not erythrocyte 
deformability.(17) The increase in MCV was significant 
in diabetic males and insignificant in diabetic females (9) 
and there was correlation between HbA1c and MCHC in 
diabetic subjects (18). In the present study, we found that 
only MCV was correlated significantly with FPG, PPG, 
HbA1c and HOMA-IR. The results were different with 
other previous studies because in this study enrolled obesity 
subjects with different glycemic control. 
 Adiponectin, synthesized in the adipose tissue, 
appears to play an important role in hyperglycemia and 
dyslipidemia, as well as in inflammatory mechanisms, 
which lead to a markedly increased atherosclerotic risk in 
diabetic subjects. Previous study supports the hypothesis 
that  increased  adiponectin  levels  might  be associated 
with better glycemic control, better lipid profile, and 
Discussion reduced inflammation in diabetic subjects.(20) In this study, we found that hs-CRP and adiponectin was not correlated 
significantly with glycemic control. The results were 
different with other previous studies because in this study 
enrolled obesity subjects with different glycemic control. 
 There are several potential limitations of this study. 
The limited sample size and the cross-sectional study design 
involving single measurement of erythrocyte indices which 
may not demonstrate a temporal relationship with glycemic 
characteristic. 
In this study, we found that there were negative correlations 
between MCV and FPG, PPG, HbA1c and HOMA-
IR, suggesting that MCV may be a potential indicator in 
finding the risk of developing micro- and macro-vascular 
complications in diabetic patients.
Conclusion
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